Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLC

Barclays PLC raised its position in Immunome, Inc. (NASDAQ:IMNM) by 125.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 105,886 shares of the company’s stock after purchasing an additional 59,016 shares during the quarter. Barclays PLC owned about 0.18% of Immunome worth $1,547,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in IMNM. Bank of New York Mellon Corp bought a new stake in shares of Immunome in the 2nd quarter worth $1,816,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Immunome in the second quarter worth about $97,000. Rhumbline Advisers acquired a new stake in Immunome in the 2nd quarter valued at about $813,000. TD Asset Management Inc boosted its position in shares of Immunome by 13.8% during the 2nd quarter. TD Asset Management Inc now owns 325,206 shares of the company’s stock valued at $3,935,000 after purchasing an additional 39,400 shares in the last quarter. Finally, Denver PWM LLC boosted its position in shares of Immunome by 95.6% during the 2nd quarter. Denver PWM LLC now owns 39,116 shares of the company’s stock valued at $473,000 after purchasing an additional 19,116 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Insider Activity

In other Immunome news, insider Robert Lechleider purchased 15,805 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was bought at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the acquisition, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Philip Tsai purchased 21,000 shares of Immunome stock in a transaction on Thursday, November 21st. The stock was bought at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the acquisition, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 102,862 shares of company stock valued at $978,045 over the last 90 days. 8.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on IMNM. Piper Sandler cut their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Stephens began coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has an average rating of “Buy” and an average target price of $28.83.

Immunome Stock Performance

NASDAQ:IMNM opened at $10.54 on Friday. The company has a market capitalization of $657.88 million, a P/E ratio of -1.30 and a beta of 1.83. The stock’s 50 day moving average price is $12.01 and its 200 day moving average price is $13.18. Immunome, Inc. has a 52 week low of $8.97 and a 52 week high of $30.96.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.